Search

Search Results

1. Clinical presentation of Warburg effect in aggressive lymphoma: a case report

   Background

   The Warburg effect is a rare condition in tumor biology, illustrated by significant lactate production in the presence of oxygen. The...

   Yenong Cao, Margaret C. Liu, ... John M. Hill Jr in Journal of Medical Case Reports

   Article Open access 23 August 2023
   

2. Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial

   The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial...

   Michael Oertel, Marita Ziepert, ... Hans Theodor Eich in Leukemia

   Article Open access 27 March 2024
   

3. Cancer-related cognitive impairment and wellbeing in patients with newly diagnosed aggressive lymphoma compared to population norms and healthy controls: an exploratory study

   Purpose

   There has been little dedicated research on cancer-related cognitive impairment in patients with aggressive lymphoma. We describe and compare...

   Priscilla Gates, Haryana. M. Dhillon, ... Karla Gough in Supportive Care in Cancer

   Article Open access 21 March 2024
   

4. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology

   Aggressive B-cell non-Hodgkin lymphomas are a heterogeneous group of diseases and our concepts are evolving as we learn more about their clinical,...

   Socorro Maria Rodriguez-Pinilla, Stefan Dojcinov, ... Eric. D. Hsi in Virchows Archiv

   Article Open access 02 August 2023
   

5. Precision Molecular Pathology of Aggressive B-Cell Lymphomas

   Written by experts in the field, Precision Molecular Pathology of Aggressive B-Cell Lymphomascontains the most recent revisions from the 5th Edition...

   Genevieve M. Crane, Sanam Loghavi in Molecular Pathology Library

   Book 2023
   

6. High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

   Type I interferon (IFN) is a potent antitumoral drug, with an important history in the treatment of hematologic malignancies. However, its...

   Willem Daneels, Alexander Van Parys, ... Fritz Offner in Experimental Hematology & Oncology

   Article Open access 03 June 2024
   

7. Effect of steroid treatment on the diagnostic yield of baseline ¹⁸f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma

   Aggressive B cell lymphoma often requires prompt steroid treatment, even before baseline ¹⁸ f-fluorodeoxyglucose (FDG) positron emission...

   Karyn Revital Geiger, Oren Pasvolsky, ... Hanna Bernstine in EJNMMI Research

   Article Open access 14 September 2022
   

8. Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation

   Background and Objective

   Adding gene expression profiles (GEPs) to the current diagnostic work-up of aggressive large B-cell lymphomas may lead to the...

   Janet Bouttell, Heather Fraser, ... Neil Hawkins in Applied Health Economics and Health Policy

   Article 28 November 2023
   

9. Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study

   Purpose

   Cancer-related cognitive impairment (CRCI) is a recognised adverse consequence of cancer and its treatment. This study assessed the...

   Priscilla Gates, Meinir Krishnasamy, ... Karla Gough in Supportive Care in Cancer

   Article Open access 14 June 2022
   

10. Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma

    SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem...

    Marta Sureda-Gómez, Patricia Balsas, ... Virginia Amador in Leukemia

    Article Open access 12 December 2022
    

11. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

    The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy...

    Robert Seifert, David Kersting, ... Michael Schäfers in Leukemia

    Article Open access 14 October 2022
    

12. Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)

    Elderly patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection....

    Huayuan Zhu, **ao Lu, ... Wenyu Shi in Annals of Hematology

    Article 22 April 2024
    

13. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series

    The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has...

    Alberto Zamò, Elena Gerhard-Hartmann, ... Hilka Rauert-Wunderlich in Virchows Archiv

    Article Open access 11 October 2022
    

14. Isolated CNS relapse of medullary aggressive high-grade B-cell lymphoma on ¹⁸F-FDG-PET/CT

    This is a case of high-risk, aggressive, high-grade medullary B-cell lymphoma presenting with new onset of neurological dysfunction following initial...

    Gerard Lambe, Simon Doran, ... Afshin Nasoodi in European Journal of Hybrid Imaging

    Article Open access 03 May 2022
    

15. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy

    Purpose

    Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r/r) aggressive B-cell...

    Thomas Walter Georgi, Lars Kurch, ... Vladan Vučinić in Journal of Cancer Research and Clinical Oncology

    Article Open access 20 January 2023
    

16. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia–lymphoma

    The prognosis of patients with aggressive adult T cell leukemia–lymphoma (ATLL) is dismal even with intensive chemotherapy. Allogeneic hematopoietic...

    Akio Onishi, Shigeo Fuji, ... Takahiro Fukuda in Annals of Hematology

    Article 15 January 2022
    

17. Laryngeal Anaplastic Lymphoma Kinase-Positive B-cell Lymphoma: Case Report and Review

    Larynx is an uncommon extranodal site for non-Hodgkin lymphoma (NHL). Anaplastic lymphoma kinase (ALK)-positive B-cell lymphoma is a rare and...

    Sunil Sam Varghese, Ashish Varghese, ... Pulkit Gupta in Indian Journal of Otolaryngology and Head & Neck Surgery

    Article 04 March 2023
    

18. Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature

    Mantle cell lymphoma (MCL) is a well-defined, non-Hodgkin lymphoma of B-cell origin displaying diverse morphological phenotypes and variable disease...

    Maria Georgaki, Vasileios Ionas Theofilou, ... Nikolaos G. Nikitakis in Head and Neck Pathology

    Article 30 October 2021
    

19. COVID19-induced immunosuppression and aggressive progression of primary cranial vault lymphoma presenting as a management challenge, a case report, and a literature review

    Background

    We needs to study Primary Large cell Non-Hodgkin’s Lymphoma of the cranial vault, which is rare, and its association with COVID19 has not...

    Vikas Chandra Jha, Mohammad Shahnawaz Alam in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

    Article Open access 14 December 2022
    

20. Aggressive B cell lymphomas—highlights from ASH 2022

    The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of...

    Michael Panny in memo - Magazine of European Medical Oncology

    Article 02 August 2023